Surveillance strategies using routine microbiology for antimicrobial resistance in low- and middle-income countries

Cherry Lim1,2,*, Elizabeth A. Ashley2,3, Raph L. Hamers2,4, Paul Turner2,5, Thomas Kesteman2,6, Samuel Akech7, Alejandra Corso8, Mayfong Mayxay3,9, Iruka N. Okeke10, Direk Limmathurotsakul1,2, H. Rogier van Doorn2,6,**

1Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
2Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
3Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit, Vientiane, Laos
4Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia
5Cambodia Oxford Medical Research Unit, Angkor Hospital for Children, Siem Reap, Cambodia
6Oxford University Clinical Research Unit, National Hospital for Tropical Diseases, Hanoi, Viet Nam
7KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya

This work is licensed under a CC BY 4.0 International license.

*Corresponding author. Cherry Lim, Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. cherry@tropmedres.ac (C. Lim).
**Corresponding author. H. Rogier van Doorn, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK. rvandoorn@oucru.org (H.R. van Doorn).

Author contributions
Conceptualization: HRvD, PT and DL. Methodology and formal analysis: CL and HRvD. Investigation: CL. Writing—original draft: CL and HRvD. Writing—second draft: CL, HRvD, EAA, PT, RLH and DL. Writing—final drafts, review and editing: CL, EAA, RLH, PT, TK, SA, AC, MM, INO, DL and HRvD.

Transparency declaration
PT, EAA, HRvD, INO, SA and RLH are investigators on a grant to design and implement clinical AMR surveillance (ACORN) from Wellcome. CL is investigator on a grant to study epidemiology and health burdens of antimicrobial resistant bacterial infection in Southeast Asia and impact of antibiotic use on patient survival from Wellcome. HRvD was principal investigator on the Fleming Fund pilot grant Vietnam from the UK Department of Health and Social Care and is a subcontractee on the Fleming Fund country grant Vietnam awarded to FHI360 from the UK Department of Health and Social Care. EAA is a subrecipient of Fleming Fund country grant Lao PDR awarded to UNOPS by the UK Department of Health and Social Care. INO is co-investigator on SEQAFRICA: regional genomic surveillance for antimicrobial resistance at for the African Continent, a Fleming Fund grant from the UK Department of Health and Social Care, PI on Minimal genomics lab for AMR surveillance and diagnostics in provincial low-income settings from BMGF, co-investigator on an NIHR Global Health Research Unit on Genomic Surveillance of Antimicrobial Resistance Consortium Award and country PI on the Severe Typhoid in Africa project from IVI. DL is investigator on a grant to evaluate barriers and enablers to the adoption of blood culture sampling recommendations from Wellcome. PT and EAA received travel expenses to present at a meeting on clinical AMR surveillance. HRvD, INO and DL are board members of the Wellcome Surveillance and Epidemiology of Drug Resistant Infections Consortium (SEDRIC). PT and EAA received a consultancy fee for SEDRIC activities on clinical AMR surveillance from Wellcome. INO is on the Surveillance Advisors Group (SAG) of BMGF. TK is a Member of Scientific Committee of the Mini-Lab project from MSF. The Mahidol Oxford Tropical Medicine Research Unit (MORU) is funded by the Wellcome Trust (106698). Oxford University Clinical Research Unit (OUCRU) is funded by the Wellcome Trust (100680). CL is funded by a Wellcome Training Research Fellowship (206736) and DL is funded by a Wellcome Intermediate Training Fellowship (101103). The funders of the investigators had no role in the study or writing of the manuscript. The corresponding authors had the final responsibility for the decision to submit for publication. No specific funding was received for conducting this review.
Abstract

Background—Routine microbiology results are a valuable source of antimicrobial resistance (AMR) surveillance data in low- and middle-income countries (LMICs) as well as in high-income countries. Different approaches and strategies are used to generate AMR surveillance data.

Objectives—We aimed to review strategies for AMR surveillance using routine microbiology results in LMICs and to highlight areas that need support to generate high-quality AMR data.

Sources—we searched PubMed for papers that used routine microbiology to describe the epidemiology of AMR and drug-resistant infections in LMICs. We also included papers that, from our perspective, were critical in highlighting the biases and challenges or employed specific strategies to overcome these in reporting AMR surveillance in LMICs.

Content—Topics covered included strategies of identifying AMR cases (including case-finding based on isolates from routine diagnostic specimens and case-based surveillance of clinical syndromes), of collecting data (including cohort, point-prevalence survey, and case—control), of sampling AMR cases (including lot quality assurance surveys), and of processing and analysing data for AMR surveillance in LMICs.

Implications—the various AMR surveillance strategies warrant a thorough understanding of their limitations and potential biases to ensure maximum utilization and interpretation of local routine microbiology data across time and space. For instance, surveillance using case-finding based on results from clinical diagnostic specimens is relatively easy to implement and sustain in LMIC settings, but the estimates of incidence and proportion of AMR is at risk of biases due to underuse of microbiology. Case-based surveillance of clinical syndromes generates informative statistics that can be translated to clinical practices but needs financial and technical support as well as locally tailored trainings to sustain. Innovative AMR surveillance strategies that can easily be implemented and sustained with minimal costs will be useful for improving AMR data availability and quality in LMICs.

Keywords
Antimicrobial resistance; Drug-resistant infections; Low- and middle-income countries; Routine microbiology; Surveillance

Introduction

Surveillance of antimicrobial resistance (AMR) is a fundamental action to inform efforts to control the spread of AMR through generation of evidence for local, national and
global guidance and action plans [1]. The main objectives of AMR surveillance include (a) providing local evidence for empirical treatment guidelines and clinical decision-making, (b) benchmarking to assess the effect of stewardship interventions, (c) estimating burden for epidemiological purposes, and (d) tracing differences and changes in space and time including outbreak detection [1,2].

Various AMR surveillance modalities have been described by the World Health Organization (WHO) [3]. Surveillance can be comprehensive (the entire population at risk) or sentinel (limited catchment area); continuous, episodic or periodic; passive (using routinely collected data) or active (planned collection of data otherwise unavailable); routine (systematic collection of data on regular basis); or enhanced (collection of additional data) [3—6]. These distinctions are important to standardize data flow of surveillance across time and space, and more importantly to guide collection of quality data [2,3]. In both low- and middle-income countries (LMICs) and in high-income settings, where more laboratories are available and microbiology testing is more often performed as part of the standard of care, passive AMR surveillance using routine microbiology data of clinical isolates from sentinel sites is the most commonly used approach [7].

At sentinel sites, AMR surveillance involves collection, validation, interpretation and reporting of susceptibility data. Microbiological testing is a crucial tool for diagnosis of bacterial infections and a source of AMR data in LMICs. Optimizing existing tools for diagnosing bacterial infections and generating bacterial identification and antimicrobial susceptibility data on site is the foundation of an AMR surveillance system [8,9]. Potential approaches for strengthening laboratory systems and services in LMIC settings have previously been extensively discussed [8—12]. Here, we focus on different strategies for AMR surveillance in humans, using data from microbiology laboratories generated as part of standard of care. We will highlight potential strengths, weaknesses, systematic errors and biases that may arise at each stage of data acquisition, and identify areas where systematic support is needed to improve and maintain the quality of AMR data from LMICs.

**Methods**

PubMed was searched for literature published before 1st November 2020, with the main theme of AMR surveillance using routine microbiology data in LMICs as search terms. Titles, abstracts, and full texts of search results were reviewed (see Supplementary Material). Moreover, we reviewed the relevant citations and AMR reports that were mentioned in the key papers and the strategies used for identifying AMR. Identified strategies are summarized in Table 1.

**Strategies for identifying AMR/drug-resistant infections (DRIs)**

There is an extensive body of literature on different strategies for identifying AMR/DRIs in a prespecified population using routine microbiology data [8,13]. In general, there are two main approaches to identifying cases of DRI: case-finding based on routinely collected clinical diagnostic specimens, and case-based surveillance of clinical syndromes (Table 1) [14].
**Case-finding based on routine diagnostic specimens**—This approach was described in the WHO Global AMR Surveillance System (GLASS): cases are identified through microbiology results from routinely collected clinical diagnostic specimens [14]. This method is easy to implement when sentinel sites have a microbiology laboratory, microbiologists and technicians, and the data are available. Often, targeted pathogens from priority specimens are surveyed, and sterile compartments such as blood and cerebrospinal fluid are the primary choice of sample owing to their higher specificity in representing true infections [2,15,16]. Combined with epidemiological and clinical data (i.e. origin of infection, age, and underlying illness), this approach can provide informative data. For instance, GLASS aims to report the frequency of infections caused by pathogens non-susceptible to individual defined antibiotics under surveillance per infection origin (community or hospital) and specimen (blood and urine) using routine microbiology data and epidemiology data collected from sentinel sites, although not all enrolled countries provide sufficient data [17]. Surveillance of stool samples collected for routine diagnostic purposes from patients with diarrhoea has been performed to monitor resistance among pathogens such as *Salmonella* spp [18]. Alternatively, a less preferable approach is the utilization of microbiology data alone (laboratory-based surveillance) without clinical and epidemiological data. Most national and supranational AMR networks rely solely on laboratory data to trace changes of antimicrobial susceptibility in space and time [7,19—22]. A recent review on supranational networks performing AMR surveillance in LMICs showed the heterogeneity of data due to lack of standards on the composition and activities of surveillance networks [7], and the majority (80%, 39/49) describe AMR based on samples sent to laboratory for clinical purposes (Table 2). Moreover, several of these supranational networks are led by pharmaceutical companies and involve collection of isolates with specific objectives (e.g. evaluating susceptibility to new antibiotics or antibiotics under development) [7]; thus use of those data for surveillance needs to be done with caution. Overall, the strategy of case-finding based on routinely collected clinical diagnostic specimens has been the most commonly used approach and has been shown useful to estimate the burden of AMR and the resistant proportions of important pathogens in studies in LMICs [23,24].

A potential concern of AMR surveillance based on routine microbiology data alone is the representativeness of data for the target population, especially when microbiological diagnosis is not performed systematically and important parameters are not captured. First, diagnostic microbiology testing may be systematically underused (i.e. patients with infectious diseases are treated with empiric antibiotics without blood culture testing) and selectively delayed (i.e. patients who have failed empiric treatments are more likely to be sampled for microbiological testing) in LMICs [25,26]. Consequently, the incidence of DRIs is underestimated and the proportion of AMR overestimated [25,27—29]. Second, in cases when the decision to collect specimens for microbiological testing is based on physicians’ subjective judgement and practices vary by physician and hospital, or are impacted by patients’ ability to afford costs for testing, difficulties in data interpretation and comparability across time and space are expected. There are several reasons for underuse of microbiology in LMICs: the costs of prescribing antibiotics may be lower than performing microbiology testing; results take too long while antibiotics may have to
be given immediately [31]; and the microbiology laboratory often returns negative culture results and this is viewed as a waste of resources with minimal returns to benefit patients. There can be an absence of financial support systems or insurance to cover the costs of diagnosis. The laboratory infrastructure may be poor or outdated [32], weak supply chains may lead to stockouts in systems and affect consistency and availability; there can be a lack of trust in the results often due to a lack of qualified microbiologists and laboratory technicians, and issues with the quality and communication of results [27,30]; lastly, in many LMICs, the costs of reagents and consumables, equipment and maintenance for the microbiology laboratory can be double that of high-income settings. Absence of local production of essential supplies imposes additional costs related to customs services and annual inflation.

**Case-based surveillance of clinical syndromes**—This approach is based on patients who present for medical care with signs and symptoms of infection. Compared to the laboratory-based approach, the case-based approach is more robust to variations in the use of microbiology and selection bias, as case identification and specimen collection time is based on more systematic and objective data collection [13,14]. Moreover, supported by clinical data, microbiology results of samples other than blood and cerebrospinal fluid can be used more effectively. The majority of supranational AMR surveillance networks that are based on case-based surveillance are currently targeted at sepsis, meningitis, and pneumonia (Table 2).

A key advantage of case-based surveillance is that the data can be used to support clinical decision-making and choice of empiric antibiotics [13,33,34]. The denominator of the data is the total number of patients with a specific type of infection or condition (i.e. patients with central lines, with community- or hospital-acquired infections) [13,14]. An example of the use of such data for empirical treatment is the weighted-incidence syndromic combination antibiogram (WISCA) that reports antimicrobial sensitivity testing (AST) data by suspected infections [33]. The numerator is the number of patients by infection site (e.g. urinary-tract infection) and by each pathogen that is susceptible to at least one of the agents in a given regimen (e.g. meropenem combined with vancomycin), and the denominator is the total number of patients by infection site with available antibiogram data for the full antibiotic regimen [33].

Increasingly, case-based surveillance has been discussed [2,8,13] and adopted in LMICs [34—38]. An example is ACORN (A Clinically Oriented antimicrobial Resistance surveillance Network), which actively identifies cases using clinical diagnosis/suspicion and actively collects clinical metadata alongside microbiology results [29].

There are challenges in implementing case-based surveillance in LMICs. First, comprehensive clinical data are not available in electronic format in most LMIC settings. Clinical data are important for defining infections, but routine documentation of such data and the use of accepted case definitions can be challenging in LMICs. The challenges include a low ratio of healthcare-workers to patients, lack of supporting tests (e.g. radiology), and lack of diagnostic guidelines to rapidly differentiate bacterial from other infections. Second, there is a lack of trained personnel and guidelines in local
languages to support case-based surveillance. Third, there is a lack of open-access, easy-to-use information technology to support clinical data capturing and storage and often limited exchange of clinical information between clinicians and the laboratory which may impact the quality/relevance of laboratory results [34]. Fourth, similar to laboratory-based surveillance, incidence of DRIs (i.e. the number of infections caused by resistant bacteria per 100 000 population) can be underestimated when there is underuse of routine microbiology testing.

Survey designs

Multiple survey designs have been used to collect AMR data in hospitals in LMICs. These include cross-sectional point-prevalence surveys (PPSs), observational cohorts, and case—control designs. PPSs have been used to measure the prevalence of healthcare-associated infections and antimicrobial use and resistance in healthcare settings in LMICs [37,39,40]. In PPS studies, patients are actively screened and identified using a case-based surveillance approach, hence the design often generates representative data that allow high comparability in space and time. The challenge of PPSs is that they require teams of well-trained staff to screen cases. Observational cohort studies using case-finding based on specimens routinely sent to laboratories for clinical purposes have been done in LMICs [16,24,25,41]. Observational cohort studies using a case-based surveillance approach to prospectively enroll cases have been done in LMICs [36,38,42—44], but are challenging for a resource-limited setting, and are often performed as parts of research projects. The implementation of cohort studies in general is particularly difficult for healthcare-associated infections because of the large variations in the time to infection among the infected patients, and because a large time investment is often needed to identify a case. Nonetheless, when performed appropriately the data generated often have large potential value in supporting empiric treatment guidelines and answering epidemiological research questions. In Asia, case-based surveillance targeting high-risk populations, such as patients admitted to intensive care units or patients with central lines, have been conducted prospectively to provide baseline evidence for prevention and control of DRIs [38,45,46]. From the literature review, we have identified some case—control studies, and most of these studies had the objective of estimating the attributable mortality of AMR infections and risk factors for acquiring AMR infections [47—49].

Sampling strategies

When population-based surveillance cannot be performed for practical reasons, various sampling approaches can be considered. Randomly sampled study cohorts and/or surveillance sites from a large target population is a common approach. Studies using lot quality assurance sampling (LQAS) have been shown to be useful in informing whether or not resistance of a pathogen to specific antibiotics is high, which is essential to inform the appropriateness of using those antibiotics for empiric treatment [50,51]. LQAS requires fewer resources and a lower budget compared to population-based surveillance, and has been shown to be feasible in LMICs [50].

The considerations for when sampling needs to be done are the sample size, sampling approach, and sampling frequency [3]. The key is to ensure the sample represents the
target population as closely as possible. In LMICs, central and referral laboratories are overrepresented, as peripheral healthcare centres often lack the infrastructure to perform routine microbiology testing, thus limiting the availability of AMR data to support local clinical decisions and to contribute to national and global estimates of AMR burden.

When attempting to estimate the health impact due to AMR infections, various sampling strategies for comparator cohorts have been suggested. WHO GLASS recently published a guideline for estimating attributable mortality of AMR bloodstream infections (BSIs) [52], in which the recommendation is to collect data from cohorts of patients without an infection and with infections caused by drug-susceptible isolates to use as comparator groups [52]. A recommended strategy is to use the exposure density sampling with matching based on patient characteristics [52,53]. This approach ensures that the time-dependent exposure (i.e. occurrence of BSIs) can be appropriately adjusted for and can produce unbiased estimates with a more realistic interpretation than random selection methods [53,54]. Alternatively, a commonly used strategy to sample patients without an infection is by randomly selecting eligible patients (sometimes matching key confounders such as length of hospitalization prior to sample collection). However, the caveat of random selection is that the interpretation is often conditioned on a future event (i.e. under the assumption that comparator groups remain within the group throughout the entire period of hospitalization) [53,54].

Strategies for processing and analysing data

At the global level, GLASS published protocols to standardize AMR surveillance data processing. In general, it is recommended that repeated isolates from individual patients are to be removed before estimating prevalence and incidence of AMR infections (deduplication), and data should be stratified by infection origin. Increasingly, open-access applications such as WHONET [55] and AMASS [56] are available to support local sentinel sites, where there is a lack of time and expertise, to process AMR surveillance data and to generate reports. It is acknowledged that there will be challenges in integrating these applications into routine practice of microbiology data collection and into the existing LIS at a local sentinel site. Innovative methods of processing and reporting AST profiles, including WISCA, have been shown to be useful but are so far not commonly applied in LMICs. Frameworks such as Microbiology Investigation Criteria for Reporting Objectively (MICRO) are useful to enhance reporting of microbiology data and comparability of AMR surveillance data, as well as providing some quality assurance [29].

At the national and global level, population catchment and pattern of healthcare utilization in the population are ideally to be included in AMR surveillance reports to interpret AMR surveillance data. However, such statistics are not commonly available in LMICs. The use of data from existing Health and Demographic Surveillance Sites (HDSS) to combine community- and hospital-based clinical and microbiology data has been recommended [8,57] but has not been sufficiently used in LMICs. An example of an HDSS network is the INDEPTH network, from which data have been utilized to estimate mortalities from malaria [58] and HIV/AIDS [59] in Africa and Asia, as well as for comparing antibiotic access and use across different regions [60]; however, so far this approach has not been used for DRIIs [61].
Support to increase use of microbiology testing

A paradigm shift in the value of microbiological testing and prioritization of the detection of drug-resistant infections is needed in many LMICs [9]. Innovative methods to improve quality and reduce the costs of microbiological testing are needed. Incentives—such as patient health insurance coverage and hospital reimbursement coverage to support the costs of microbiology testing—may support this shift and motivate the use of microbiology testing in LMIC settings. A healthy and dedicated liaison between the qualified microbiology laboratory and clinicians is also crucial to increase mutual trust and to optimize the use of existing diagnostic tools [62—64]. Moreover, a clear potential advancement in career pathways for the qualified microbiologist and laboratory technicians could further enhance trust and uptake of microbiology results.

While the use of microbiology in many LMICs is gradually increasing, essential parameters such as blood culture use rate and rates of AMR stratified by antibiotic usage should also be used to standardize the measures of prevalence and incidence, and increase the comparability of AMR burden across space and time [25].

Social and behavioural changes on the attitudes and practices of antibiotic usage and microbiological testing are needed and may be accelerated with diagnostic and antibiotic stewardship programmes. Systematic trainings to increase awareness on the significance of microbiology testing among all stakeholders, from students to senior specialists, may motivate the use of microbiology.

Investments in improving microbiology quality and use through expensive automated equipment do not always deliver, as operating costs and costs of maintenance and consumables have not been taken into account. Maintaining power supply and cold chain often remains challenging. Innovative tools to simplify microbiological diagnosis [65] and to conserve diagnostic reagents will be useful to fill the AMR data gap from LMIC settings.

Support to establish and maintain case-based surveillance

The incremental value of the case-based approach can be significant if implementation challenges can be overcome [13]. Trainings on diagnostic stewardship and pragmatic definitions of suspected bacterial infections would be important in LMIC settings. Devices, software and technical support to capture and store clinical data are needed. Most importantly, financial support is needed to build the local capacity, including establishing surveillance teams and increasing availability of diagnostic tools, in order to ensure a sustainable case-based surveillance system. Increasingly, different international organizations have devoted efforts to strengthening AMR surveillance in LMICs. An example is the Fleming Fund (UK government), which supports 24 LMICs in Africa and Asia [66].

Support to strengthen laboratory quality and microbiology data quality

Quality assurance and control (QA/QC) are essential to ensure accurate identification of pathogens and AST profiles, and need to be improved in sentinel surveillance sites in LMICs. Commercial QA/QC schemes and accreditation programmes are available, but often
unaffordable for laboratories in LMICs. Training and support to ensure quality performance and methods of bacterial identification and AST are needed for laboratories in LMICs [67]. Web-based tools such as the laboratory quality stepwise implementation tool and other quality management-strengthening programmes, are useful to guide laboratories, especially those in LMIC settings, towards implementing quality management systems [68—70]. In addition, prioritizing the microbiology testing in the local setting, increasing the number of microbiology testing facilities, and strengthening the local capacity of the existing laboratory system are needed.

Verifying AST results of bacterial isolates is an important component of surveillance to ensure quality data are generated. However, data verification and highlighting isolates with unusual AST results can be a complicated and time-consuming process to perform manually. Commercial laboratory information management systems with functions to support microbiology data verification are unaffordable for many hospitals in LMICs. The openaccess WHONET programme has functions to support data quality checks [55]. Open-access, offline, and user-friendly tools that can automatically process and analyse microbiology data can be useful in resource-limited settings in generating AMR surveillance reports for local use and sharing in a timely fashion.

Finally, there is a lack of evaluation frameworks for continuous AMR surveillance systems in LMICs. Regular evaluations on the performance of AMR surveillance systems in LMICs would be useful to identify limitations and areas for improvement as well as to quantify and qualify progress when it occurs. Examples of evaluation tools for AMR surveillance network are the AMR Progressive Management Pathway tool developed by the Food and Agriculture Organization of the United Nations, NEOH and SURV-TOOLS [71]. The implementation of such tools in LMIC settings is uncommon.

**Conclusion**

Several strategies for conducting AMR surveillance have been used in LMICs, with the majority adopting the isolate- or samplebased approach using microbiology data from routine clinical diagnostics. Attempts to transition to a case-based approach are receiving increased attention, but significant challenges remain in settings where resources, expertise and experience are limited. Guidelines, trainings, and local capacity building are useful to support such transitions. Moreover, tertiary hospitals, research institutions, and pharmaceutical companies with microbiology testing and involved in AMR data collection could play a role in leading and supporting the transition to case-based AMR surveillance in surrounding facilities within their reach. In parallel, it is important to strengthen diagnostic capacity, reduce costs and otherwise incentivize routine microbiology testing, especially when most surveillance still relies on a laboratory-based approach in central reference hospitals. Strategies to maximize usage of locally existing resources and data could narrow the data gap. Improvements in AMR data generated from LMICs also depends on innovative and collaborative clinical research on strategies that can require minimal financial and human resource requirements while data quality is maintained. For instance, the LQAS has shown applicability in LMICs to inform empirical antibiotic treatment guidelines in a local setting, and WISCA could be an informative strategy for presenting AMR patterns to guide...
treatment decisions. Experience from ACORN implementation and further roll-out will inform what is needed for this transition in LMICs. Finally, innovative AMR surveillance tools and strategies that can be easily implemented and maintained in resource-limited settings will be useful for improving AMR data availability and quality to support local, national and global action plans in controlling AMR.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We would like to thank Pham Hoang Giang, Nguyen Thi Quynh Trang, Nguyen Dao Thanh Thuong, and Nguyen Lan Chi for their help with the literature review and screening through over 2000 abstracts for this narrative review.

References

[1]. The review on antimicrobial resistance. Tackling drug-resistant infections globally: final report and recommendation. 2016.
[2]. World Health Organization. Global antimicrobial resistance surveillance system. GLASS; 2015.
[3]. World Health Organization. Surveillance standards for antimicrobial resistance. 2002.
[4]. Mather AE, Reeve R, Mellor DJ, Matthews L, Reid-Smith RJ, Dutil L, et al. Detection of rare antimicrobial resistance profiles by active and passive surveillance approaches. PloS One. 2016; 11 e0158515 [PubMed: 27391966]
[5]. Lewis D. Antimicrobial resistance surveillance: methods will depend on objectives. J Antimicro Chemother. 2002; 49: 3–5.
[6]. Doherr MG, Audige L. Monitoring and surveillance for rare health-related events: a review from the veterinary perspective. Philos Trans R Soc Lond Ser B Biol Sci. 2001; 356: 1097–106. [PubMed: 11516387]
[7]. Ashley EA, Recht J, Chua A, Dance D, Dhorda M, Thomas NV, et al. An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000. J Antimicro Chemother. 2018; 73: 1737–49. [PubMed: 29514279]
[8]. Scale AC, Gordon NC, Islam J, Peacock SJ, Scott JAG. AMR surveillance in low and middle-income settings—a roadmap for participation in the Global Antimicrobial Surveillance System (GLASS). Wellcome Open Res. 2017; 2: 92. [PubMed: 29062918]
[9]. Okeke IN, Feasey N, Parkhill, Turner P, Limmathurotsakul D, Alison Georgiou P, et al. Leapfrogging laboratories: the promise and pitfalls of high-tech solutions for antimicrobial resistance surveillance in low-income settings. BMJ Glob Health. 2020; 5
[10]. Nkengasong JN, Nsubuga P, Nwanyanwu O, Gershy-Damet G-M, Roscigno G, Bultery M, et al. Laboratory systems and services are critical in global health: time to end the neglect? Am J Clin Pathol. 2010; 134: 368–73. [PubMed: 20716791]
[11]. Petti CA, Polage CR, Quinn TC, Ronald AR, Sande MA. Laboratory medicine in Africa: a barrier to effective health care. Clin Infect Dis. 2006; 42: 377–82. [PubMed: 16392084]
[12]. Saeed DK, Hasan R, Naim M, Zafar A, Khan E, Jabeen K, et al. Readiness for antimicrobial resistance (AMR) surveillance in Pakistan; a model for laboratory strengthening. Antimicrob Resist Infect Control. 2017; 6: 101. [PubMed: 29021895]
[13]. Ryu S, Cowling BJ, Wu P, Olesen S, Fraser C, Sun DS, et al. Case-based surveillance of antimicrobial resistance with full susceptibility profiles. JAC Antimicrob Resist. 2019; 1 dz070 [PubMed: 32280945]
[14]. World Health Organization. The global antimicrobial resistance surveillance system (GLASS): manual for early implementation. 2015.
[15]. European Center for Disease prevention and Control. Surveillance of antimicrobial resistance in Europe 2018. 2018.

[16]. Alisraeli B, Bagheri Nejad S, Combscure C, Graefmans W, Attar H, Donaldson L, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet. 2011; 377: 228–41. [PubMed: 21146207]

[17]. World Health Organization. Global antimicrobial resistance surveillance system (GLASS) report: early implementation 2017—2018. 2018.

[18]. Biedenbach DJ, Toleman M, Walsh TR, Jones RN. Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997—2004). Diag Microbiol Infect Dis. 2006; 54: 13–21.

[19]. Singh-Moodley A, Ismail H, Perovic O. An overview of antimicrobial resistance surveillance among healthcare-associated pathogens in South Africa. Afr J Lab Med. 2018; 7: 741. [PubMed: 30568896]

[20]. Gandra S, Alvarezagaria G, Turner P, Joshi J, Limmathurotsakul D, van Doorn HR. Antimicrobial resistance surveillance in low- and middle-income countries: progress and challenges in eight South Asian and Southeast Asian countries. Clin Microbiol Rev. 2020; 33.

[21]. Pan American Health Organization. Magnitude and trends of antimicrobial resistance in Latin America—ReLAVERA 2014, 2015, 2016 summary report. 2020. https://www.paho.org/en/documents/magnitude-and-trends-antimicrobial-resistance-latin-america-relavera-2014-2015-2016

[22]. Truppa C, Abo-Shehada MN. Antimicrobial resistance among GLASS pathogens in conflict and non-conflict affected settings in the Middle East: a systematic review. BMC Infect Dis. 2020; 20: 936. [PubMed: 33297983]

[23]. Lim C, Takahashi E, Hongsuwan M, Wuthiekanun V, Thamlikitkul V, Hinjoy S, et al. Epidemiology and burden of multidrug-resistant bacterial infection in a developing country. Elife. 2016; 5

[24]. Musicha P, Cornick JE, Bari-Zeev N, French N, Masesa C, Denis B, et al. Trends in antimicrobial resistance in bloodstream infection isolates at a large urban hospital in Malawi (1998-2016): a surveillance study. Lancet Infect Dis. 2017; 17: 1042–52. [PubMed: 28818544]

[25]. Lim C, Hantrakun V, Teerawattanasook N, Srisamang P, Teparrukkul P, Sumpradit N, et al. Impact of low blood culture usage on rates of antimicrobial resistance. J Infect. 2021; 82: 355–62. [PubMed: 33278401]

[26]. Teerawattanasook N, Tauran PM, Teparrukkul P, Wuthiekanun V, Dance DAB, Afir M, et al. Capacity and utilization of blood culture in two referral hospitals in Indonesia and Thailand. Am J Trop Med Hyg. 2017; 97: 1257–61. [PubMed: 28726262]

[27]. Ashley EA, McLean A, Chiara F, Peasey N, Jaoko W, Opintan JA, et al. Setting priorities for patient-centered surveillance of drug-resistant infections. Int J Infect Dis. 2020; 97: 60–5. [PubMed: 32502663]

[28]. Hindler JF, Stelling J. Analysis and presentation of cumulative antibiograms: a new consensus guideline from the Clinical and Laboratory Standards Institute. Clin Infect Dis. 2007; 44: 867–73. [PubMed: 17304629]

[29]. Turner P, Fox-Lewis A, Shrestha P, Dance DAB, Wangrangsimakul T, Cusack TP, et al. Microbiology Investigation Criteria for Reporting Objectively (MICRO): a framework for the reporting and interpretation of clinical microbiology data. BMC Med. 2019; 17: 70. [PubMed: 30922309]

[30]. Chaw PS, Schlinkmann MKM, Raupach-Rosin H, Karch A, Pletz MW, Huebner J, et al. Knowledge, attitude and practice of Gambian health practitioners towards antibiotic prescribing and microbiological testing: a cross-sectional survey. Trans R Soc Trop Med Hyg. 2017; 111: 117–24. [PubMed: 28633334]

[31]. Abera B, Kibret M, Mulu W. Knowledge and beliefs on antimicrobial resistance among physicians and nurses in hospitals in Amhara Region, Ethiopia. BMC Pharmacol Toxicol. 2014; 15: 26. [PubMed: 24887310]
[32]. Ombelet S, Ronat JB, Walsh T, Yansouni CP, Cox J, Vlieghe E, et al. Clinical bacteriology in low-resource settings: today's solutions. Lancet Infect Dis. 2018; 18: e248–58. [PubMed: 29519767]

[33]. Hebert C, Ridgway J, Vekhter B, Brown EC, Weber SG, Robicsek A. Demonstration of the weighted-incidence syndromic combination antibiogram: an empiric prescribing decision aid. Infect Control Hosp Epidemiol. 2012; 33: 381–8. [PubMed: 22418634]

[34]. Turner P, Ashley EA, Cellhay OJ, Douangnouvang A, Hamers RL, Ling CL, et al. ACORN (A Clinically-Oriented Antimicrobial Resistance Surveillance Network): a pilot protocol for case based antimicrobial resistance surveillance. Wellcome Open Res. 2020; 5: 13. [PubMed: 32509968]

[35]. Talaat M, El-Shokry M, El-Kholy J, Ismail G, Kotb S, Hafez S, et al. National surveillance of health care-associated infections in Egypt: developing a sustainable program in a resource-limited country. Am J Infect Control. 2016; 44: 1296–301. [PubMed: 27339791]

[36]. Renner LA, Usuf E, Mohammed NI, Ansong D, Dankwah T, Kusah JT, et al. Hospital-based surveillance for pediatric bacterial meningitis in the era of the 13-valent pneumococcal conjugate vaccine in Ghana. Clin Infect Dis. 2019; 69: S89–96. [PubMed: 31505622]

[37]. Turner P, Ashley EA, Cellhay OJ, Douangnouvang A, Hamers RL, Ling CL, et al. ACORN (A Clinically-Oriented Antimicrobial Resistance Surveillance Network): a pilot protocol for case based antimicrobial resistance surveillance. Wellcome Open Res. 2020; 5: 13. [PubMed: 32509968]

[38]. Kumar S, Sen P, Gaind R, Verma PK, Gupta P, Suri PR, et al. Prospective surveillance of device-associated health care-associated infection in an intensive care unit of a tertiary care hospital in New Delhi, India. Am J Infect Control. 2018; 46: 202–6. [PubMed: 29046215]

[39]. Saleem Z, Godman B, Hassali MA, Hashmi FK, Azhar F, Rehman IU. Point prevalence surveys of health-care-associated infections: a systematic review. Pathog Glob Health. 2019; 113: 191–205. [PubMed: 31215326]

[40]. Le NK, Hf W, Vu PD, Khu DT, Le HT, Hoang BT, et al. High prevalence of hospital-acquired infections caused by gram-negative carbapenem resistant strains in Vietnamese pediatric ICUs: a multi-centre point prevalence survey. Medicine. 2016; 95 e4099 [PubMed: 27399106]

[41]. Fox-Lewis A, Takata J, Miliya T, Carevic B, Askarian M, Cottle L, et al. Surveillance, control and management of infections in intensive care units in Southern Europe, Turkey and Iran—a prospective multicenter point prevalence study. J Infect. 2014; 68: 131–40. [PubMed: 24269951]

[42]. Stewardson AJ, Marimuthu K, Sengupta S, Allignol A, El-Bouseary M, Carvalho MJ, et al. Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study. Lancet Infect Dis. 2019; 19: 601–10. [PubMed: 31047852]

[43]. Li Y, Cao X, Ge H, Jiang Y, Zhou H, Zheng W. Targeted surveillance of nosocomial infection in intensive care units of 176 hospitals in Jiangsu province, China. J Hosp Infect. 2018; 99: 36–41. [PubMed: 29051092]

[44]. Parajuli NP, Acharya SP, Dahal S, Singh JP, Mishra SK, Kattel HP, et al. Epidemiology of device-associated infections in an intensive care unit of a teaching hospital in Nepal: a prospective surveillance study from a developing country. Am J Infect Control. 2017; 45: 1024–9. [PubMed: 28431848]

[45]. Cezario RC, Duarte De Morais L, Ferreira JC, Costa-Pinto RM, da Costa Darini AL, Gontijo-Filho PP. Nosocomial outbreak by imipenem-resistant metallo-beta-lactamase-producing Pseudomonas aeruginosa in an adult intensive care unit in a Brazilian teaching hospital. Enferm Microbiol Clin. 2009; 27: 269–74. [PubMed: 19386392]

[46]. Snyder BM, Montague BT, Anandan S, Madabhushi AG, Pragasam AK, Vergheese VP, et al. Risk factors and epidemiologic predictors of blood stream infections with New Delhi.
Metallo-β-lactamase (NDM-1) producing Enterobacteriaceae. Epidemiol Infect. 2019; 147: e137. [PubMed: 30869056]

[49]. Naylor NR, Atun R, Zhu N, Kulasabathan K, Silva S, Chatterjee A, et al. Estimating the burden of antimicrobial resistance: a systematic literature review. Antimicrob Resist Infect Control. 2018; 7: 58. [PubMed: 29713465]

[50]. Ginting F, Sugiani AK, Bijl G, Saragih RH, Kusumawati RL, Parwati I, et al. Rethinking antimicrobial resistance surveillance: a role for lot quality assurance sampling. Am J Epidemiol. 2019; 188: 734–42. [PubMed: 30608516]

[51]. van Leth F, den Heijer C, Stobberingh E, Geerlings S, Schultz C. Rapid assessment of antimicrobial resistance prevalence using a Lot Quality Assurance sampling approach. Future Microbiol. 2017; 12: 369–77. [PubMed: 28339294]

[52]. World Health Organization. GLASS method for estimating attributable mortality of antimicrobial resistant bloodstream infections. 2020.

[53]. Wolkewitz M, Beyersmann J, Gastmeier P, Schumacher M. Efficient risk set sampling when a time-dependent exposure is present: matching for time to exposure versus exposure density sampling. Methods Inf Med. 2009; 48: 438–43. [PubMed: 19657545]

[54]. de Kraker MEA, Lipsitch M. Burden of antimicrobial resistance: compared to what? Epidemiol Rev. 2021.

[55]. O’Brien TF, Stelling JM. WHONET: an information system for monitoring antimicrobial resistance. Emerg Infect Dis. 1995; 1: 66.

[56]. Lim C, Miliya T, Chansamouth V, Aung MT, Karkey A, Teparrukkul P, et al. Automating the generation of antimicrobial resistance surveillance reports: proof-of-concept study involving seven hospitals in seven countries. J Med Internet Res. 2020; 22 e19762 [PubMed: 33006570]

[57]. Grundmann H, Klugman KP, Walsh T, Ramsh Pardo P, Siguache B, Khan W, et al. A framework for global surveillance of antibiotic resistance. Drug Resist Updat. 2011; 14: 79–87. [PubMed: 21482177]

[58]. Streatfield PK, Khan WA, Bhuiya A, Hanifi SM, Alam N, Diboulo E, et al. Malaria mortality in Africa and Asia: evidence from INDEPTH health and demographic surveillance system sites. Glob Health Action. 2014; 7 25369 [PubMed: 25377329]

[59]. Streatfield PK, Khan WA, Bhuiya A, Hanifi SM, Alam N, Millogo O, et al. HIV/AIDS-related mortality in Africa and Asia: evidence from INDEPTH health and demographic surveillance system sites. Glob Health Action. 2014; 7 25370 [PubMed: 25377330]

[60]. Wertheim HFL, Chuc NTK, Pupply C, Khan WA, Gyapong M, Asante KP, et al. Community-level antibiotic access and use (ABACUS) in low- and middle-income countries: finding targets for social interventions to improve appropriate antimicrobial use—an observational multi-centre study. Wellcome Open Res. 2017; 2: 58. [PubMed: 29707652]

[61]. Sankoh O, Byass P. Cause-specific mortality at INDEPTH health and demographic surveillance system sites in Africa and Asia: concluding synthesis. Glob Health Action. 2014; 7 25590 [PubMed: 25377341]

[62]. Yansouni CP, Seifu D, Libman M, Alemayehu T, Gizaw S, Johansen ØH, et al. A feasible laboratory-strengthening intervention yielding a sustainable clinical bacteriology sector to support antimicrobial stewardship in a large referral hospital in Ethiopia. Front Public Health. 2020; 8: 258. [PubMed: 32656174]

[63]. Gebretekle GB, Haile Mariam D, Abebe Taye W, Mulu Fentie A, Amogne Dega W, Alemayehu T, et al. Half of prescribed antibiotics are not needed: a pharmacist-led antimicrobial stewardship intervention and clinical outcomes in a referral hospital in Ethiopia. Front Public Health. 2020; 8: 109. [PubMed: 32328474]

[64]. Semret M, Abebe W, Kong LY, Alemayehu T, Beyene T, Libman MD, et al. Prolonged empirical antibiotic therapy is correlated with bloodstream infections and increased mortality in a tertiary care hospital in Ethiopia: bacteriology testing matters. JAC Antimicrob Resist. 2020; 2

[65]. Natale A, Ronat J-B, Mazoyer A, Rochard A, Boillot B, Hubert J, et al. The Mini-Lab: accessible clinical bacteriology for low-resource settings. The Lancet Microbe. 2020; 1: e56–8. [PubMed: 35544155]
[66]. Seale AC, Hutchison C, Fernandes S, Stoesser N, Kelly H, Lowe B, et al. Fleming Fund: supporting surveillance capacity for antimicrobial resistance. An analysis of approaches to laboratory capacity strengthening for drug resistance infections in low and middle income countries. 2016.

[67]. Perovic O, Yahaya AA, Viljoen C, Ndihokubwayo JB, Smith M, Coulibaly SO, et al. External quality assessment of bacterial identification and antimicrobial susceptibility testing in African National Public Health Laboratories, 2011—2016. Trop Med Infect Dis. 2019; 4.

[68]. World Health Organization. Strengthening health security by implementing the international health regulations. Laboratory quality stepwise implementation tool 2005. 2005. available from, https://www.who.int/ihr/lyon/hls_lqsi/en/

[69]. Yao K, Maruta T, Luman ET, Nkengasong JN. The SLMTA programme: transforming the laboratory landscape in developing countries. Afr J Lab Med. 2014; 3: 194.

[70]. Gagetti P, Pasteran F, Ceriana P, Prieto M, Cipolla L, Tuduri E, et al. [Evolution of the performance of Latin America Reference Laboratories in the detection of mechanisms of antimicrobial resistance Evolução do desempenho dos Laboratorios de Referenda na América Latina na detecção de mecanismos de resistencia antimicrobiana]. Rev Panam Salud Publica. 2020; 44: e42. [PubMed: 32973896]

[71]. Nielsen LR, Alban L, Ellis-Iversen J, Mintiens K, Sandberg M. Evaluating integrated surveillance of antimicrobial resistance: experiences from use of three evaluation tools. Clin Microbiol Infect. 2020; 26: 1606–11. [PubMed: 32213319]
Table 1
Summary on strength and weakness of various strategies for antimicrobial resistance (AMR) surveillance

| Strategies for identifying AMR infections: | Strength | Weakness |
|-------------------------------------------|----------|----------|
| Case-finding based on specimens sent routinely to laboratories for clinical purposes | - Relatively easy to implement and sustain in LMICs | - Estimates on incidence of infection and proportion of AMR can be influenced by utilization of microbiology testing and empiric antibiotic prescription behaviour |
| | - Generate basic data when only laboratory data is available | |
| | - Generate informative data (e.g. origin of infection) when epidemiological and clinical data (e.g. hospital admission date) are also available | - Comparability across space and time is often limited in LMIC settings |
| | - Generate useful statistics including proportion of samples with growth of non-susceptible bacteria of the species and antibiotic under surveillance per specimen type; proportion of sampled patients with positive culture of any pathogenic bacteria per specimen type (in the cases when data on negative growth is available); and frequency of patients with growth of non-susceptible bacteria per specimen type, species and antibiotic | - Capability of providing local evidence for empiric treatment guidelines and clinical decision-making is limited, especially in cases when there is a lack of clinical data |
| | - Capable of generating data for outbreak detection, but potential influences on the data due to the use of microbiology testing and empirical antibiotic prescription behaviour should considered carefully | |
| Case-based surveillance of clinical syndromes | - Relatively robust to variations in use of microbiology testing as case definitions allow more systematic and objective data collection | - Can be labour-intensive and costly to implement and sustain in LMICs |
| | - Informative data can be generated to inform clinical decisions | - Needs investments on training, guidelines, and diagnostic capacity in LMIC settings |
| | - Capable of addressing different objectives of AMR surveillance including (a) providing local evidence for empiric treatment guidelines; (b) benchmarking to assess the effect of stewardship interventions; (c) estimating health impact of AMR infection; and (d) tracing differences and changes in space and time | |

Sampling strategies:

| DRI: include consecutive samples | - Easy to perform | - At risk of bias due to clinical sampling behaviour |
| DRI: lot quality assurance sampling (LQAS) | - Requires small sample size for informative estimates to inform empiric treatment policy | - Definition of thresholds defining the ‘low’ or ‘high’ prevalence of resistance could be challenging to determine |
| Comparator cohort: exposure density sampling | - Ensures a more accurate estimation for health burdens due to DRI | - Would need training and detailed protocol for LMIC settings |

Strategies for reporting AST data:

| Report susceptibility to individual antibiotic | - Easy to generate the statistics | - Limited capability in translating to clinical practice |
| Weighted-incidence syndromic combination antibiogram (WISCA) | - Statistics generated can be translated to clinical practice | - May be difficult to generate in LMICs where there is a lack of expert and open-access applications to process data |

AST, antibiotic susceptibility testing; DRI, drug-resistant infection; LMIC, low- and middle-income countries.
### Table 2

Strategies for identifying antimicrobial-resistant infections used by antimicrobial resistance (AMR) surveillance networks (a list adapted from Ashley et al., 2018 [7], stratified by strategy used and arranged in alphabetical order) in low- and middle-income countries (LMICs)

| Name                                                                 | Year        | Target infections/or ganisms                                                                 | Strategy used to identify AMR cases                                                                 |
|----------------------------------------------------------------------|-------------|---------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| A Clinically Oriented Antimicrobial Resistance Surveillance Network (ACORN) | 2019 ongoing | Sepsis; meningitis; pneumonia (both community-acquired and hospital-acquired)                | Case-based surveillance of clinical syndrome                                                        |
| Antimicrobial Resistance Epidemiological Survey on Cystitis (ARESC), European Society for Infection in Urology | 2003—2006   | Uncomplicated cystitis                                                                       | Case-based surveillance of clinical syndrome                                                        |
| Bacterial Infections and Antibiotic-Resistant Diseases Among Young Children in Low-Income Countries (BIRDY), Institut Pasteur International Network | 2012 ongoing | Sepsis; meningitis; pneumonia                                                                | Case-based surveillance of clinical syndrome                                                        |
| Burden of Antibiotic Resistance in Neonates from Developing Societies | 2015—2018   | Neonatal sepsis                                                                             | Case-based surveillance of clinical syndrome                                                        |
| Clinical Information Network—Antimicrobial Resistance (CINAMR) project | 2021—2023¹ | A project that may feed data into other initiative such as ACORN network and WHO GLASS      | Case-based surveillance of clinical syndrome                                                        |
| Diseases of the Most Impoverished Typhoid Study Group and Multicentre Shigellosis Surveillance Study (DOMI), International Vaccine Institute, Republic of Korea | 2001 —2004 | Typhoid fever                                                                              | Case-based surveillance of clinical syndrome                                                        |
| Global Point Prevalence Survey of Antimicrobial Consumption and Resistance (Global-PPS), University of Antwerp | 2015 ongoing | Hospital-acquired infections                                                                 | Case-based surveillance of clinical syndrome                                                        |
| Hib Impact Project (Pediatric Bacterial Meningitis Surveillance Network) | 2006—2008   | Meningitis                                                                                  | Case-based surveillance of clinical syndrome                                                        |
| International Nosocomial Infection Control Consortium (INICC)         | 2002 ongoing | Clinically defined pneumonia; laboratory-confirmed bloodstream infection; clinical sepsis; symptomatic urinary tract infection | Case-based surveillance of clinical syndrome                                                        |
| Proof-of-Principle routine diagnostics project for antimicrobial resistance surveillance (PoP project), CAESAR | 2018 ongoing | Suspected bloodstream infections                                                             | Case-based surveillance of clinical syndrome                                                        |
| South Asian Pneumococcal Alliance (SAPNA), GAVI Alliance             | 2004—2009   | Sepsis; meningitis; pneumonia (children 2—5 years old)                                       | Case-based surveillance of clinical syndrome                                                        |
| Surgical Unit-based Safety Programme (SUSP)                          | 2013—2015   | Surgical site infection                                                                     | Case-based surveillance of clinical syndrome                                                        |
| The Alexander Project, GlaxoSmithKline                               | 1992—2002   | Bacteria                                                                                    | Case-finding based on specimens sent to laboratory for clinical purposes                            |
| Asian Network for Surveillance of Resistant Pathogens (ANSORP), Sungkyunkwan University, Korea | 1996 ongoing | Bacteria                                                                                    | Case-finding based on specimens sent to laboratory for clinical purposes                            |
| Antibiotic Resistance in the Mediterranean Region (ARMed), Infection Control Unit, Mater Dei Hospital, Msida, Malta | 2003—2007   | Bacteria                                                                                    | Case-finding based on specimens sent to laboratory for clinical purposes                            |
| Name                                                                 | Year       | Target infections/organisms | Strategy used to identify AMR cases                                                                 |
|----------------------------------------------------------------------|------------|-----------------------------|------------------------------------------------------------------------------------------------------|
| ARTEMIS Global Antifungal Surveillance Programme (ARTEMIS)           | 1997—2005 | Fungi                       | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| Assessing Worldwide Antimicrobial Resistance and Evaluation Programme (AWARE), International Health Management Associates, Inc. (IHMA) | 2012 ongoing | Bacteria                    | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| Central Asian and Eastern European Surveillance of Antimicrobial Resistance (CAESAR) | 2013 ongoing | Bacteria                    | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| Caribbean Public Health Agency (CARPHA)                             | 2013 ongoing | Bacteria                    | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) | 2009—2010 | Bacteria                    | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| Centre for Disease Dynamics, Economics and Policy (CDDEP)/ResistanceMap | 1999 ongoing | Bacteria                    | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| Community-Based Surveillance of Antimicrobial Use and Resistance in Resource-Constrained Settings, WHO | 2002—2005 | Bacteria                    | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| Comparative Activity of Carbapenem Testing (COMPACT and COMPACT II), Janssen Asia-Pacific | 2008—2010 | Bacteria                    | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| International Daptomycin Surveillance Programmes, JMI Laboratories   | 2011 ongoing | Bacteria                    | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| European Antimicrobial Resistance Surveillance Network (EARS-Net), ECDC | 1999 ongoing | Bacteria                    | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| Enter-Net International Surveillance Network, Health Protection Agency, UK | 1993—2007 | Bacteria                    | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| Food- and Waterborne Diseases and Zoonoses Network (FWD-Net), ECDC   | 2007 ongoing | Bacteria                    | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| Gonococcal Antimicrobial Surveillance Programme (GASP), WHO          | 1992 ongoing | Bacteria                    | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| International Network For Optimal Resistance Monitoring (INFORM), IHMA | 2012—2014 | Bacteria                    | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| International Network for the Study and Prevention of Emerging Antimicrobial Resistance (INSPEAR), US CDC | 1998—2010 | Bacteria                    | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| In Vitro Activity of Oral Antimicrobial Agents Against Pathogens Associated With Community-Acquired Upper Respiratory Tract and Urinary Tract Infections: A Five Country Surveillance Study, IHMA | 2012—2013 | Bacteria                    | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| Multiyear, Multinational Survey of the Incidence and Global Distribution of MBL-Producing Enterobacteriaceae and Pseudomonas aeruginosa, IHMA | 2012—2014 | Bacteria                    | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia and Burkholderia cepacia species complex isolates from a global surveillance programme (2013), JMI Laboratories | 2013       | Bacteria                    | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| Meropenem Yearly Susceptibility Test Information Collection (MYSTIC), AstraZeneca | 1997—2008 | Bacteria                    | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| Mortality from Bacterial Infections Resistant to Antibiotics (MBIRA)  | 2020 ongoing | Gram-negative enteric bacteria | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| NosMed Pilot Survey in the Eastern Mediterranean Area, Universite Claude Bernard Lyon I | 2003—2004 | Bacteria                    | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| Programme to Assess Ceftolozane/Tazobactam Susceptibility (PACTS), Cubist Pharmaceuticals | 2012 ongoing | Bacteria                    | Case-finding based on specimens sent to laboratory for clinical purposes                              |
| Name                                                                 | Year         | Target infections/organisms | Strategy used to identify AMR cases                                      |
|----------------------------------------------------------------------|--------------|------------------------------|-------------------------------------------------------------------------|
| Pan-European Antimicrobial Resistance Using Local Surveillance (PEARLS), Wyeth Pharmaceuticals | 2001—2002    | Bacteria                     | Case-finding based on specimens sent to laboratory for clinical purposes |
| Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin (PROTEKT), Sanofi-Aventis | 1999—2004    | Bacteria                     | Case-finding based on specimens sent to laboratory for clinical purposes |
| Red Latinoamericana de Vigilancia de la Resistencia a los Antimicrobianos (ReLAVRA), PAHO          | 1996 ongoing | Bacteria                     | Case-finding based on specimens sent to laboratory for clinical purposes |
| Study on Antimicrobial Resistance in Staphylococcus aureus(SARISA), LEO Pharma (Copenhagen)       | 1996 ongoing | Bacteria                     | Case-finding based on specimens sent to laboratory for clinical purposes |
| SENTRY Antimicrobial Surveillance Programme, JMI laboratories         | 1997 ongoing | Bacteria, fungi              | Case-finding based on specimens sent to laboratory for clinical purposes |
| Sistema de Redes de Vigilancia de los Agentes Responsables de Neumonias y Meningitis Bacterianas (SIREVA and SIREVA II), PAHO | 1993—ongoing | Bacteria                     | Case-finding based on specimens sent to laboratory for clinical purposes |
| Study for Monitoring Antimicrobial Resistance Trends (SMART), Merck & Co. Inc. | 2002—2011    | Bacteria                     | Case-finding based on specimens sent to laboratory for clinical purposes |
| Survey of Antibiotic Resistance (SOAR), GlaxoSmithKline             | 2002 ongoing | Bacteria                     | Case-finding based on specimens sent to laboratory for clinical purposes |
| International Solithromycin Surveillance Programmes, JMI Laboratories, USA | 2011 ongoing | Bacteria                     | Case-finding based on specimens sent to laboratory for clinical purposes |
| TARGETed Surveillance Study, GR Micro Ltd, UK                        | 2003—2007    | Bacteria                     | Case-finding based on specimens sent to laboratory for clinical purposes |
| Tigecycline Evaluation and Surveillance Trial (TEST), IHMA          | 2004 ongoing | Bacteria                     | Case-finding based on specimens sent to laboratory for clinical purposes |
| Typhoid Fever Surveillance in Africa Programme (TSAP), International Vaccine Institute, Korea | 2009 ongoing | Bacteria                     | Case-finding based on specimens sent to laboratory for clinical purposes |
| WHO Western Pacific Regional Programme for Surveillance of Antimicrobial Resistance | 1991—1998    | Bacteria                     | Case-finding based on specimens sent to laboratory for clinical purposes |
| ZyvoxVR Annual Appraisal of Potency and Spectrum (ZAAPS), JMI Laboratories, USA and Pfizer | 2004 ongoing | Bacteria                     | Case-finding based on specimens sent to laboratory for clinical purposes |

A tentative timeline ([https://sedric.org.uk/amr-surveillance-projects/](https://sedric.org.uk/amr-surveillance-projects/)).